Showing 5361-5370 of 7902 results for "".
- Valeant Pharmaceuticals Announces FDA Approval Of Jublia® for the Treatment of Onychomycosishttps://practicaldermatology.com/news/20140609-valeant_pharmaceuticals_announces_fda_approval_of_jublia_for_the_treatment_of_onychomycosis/2459213/Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that that its wholly owned subsidiary, Valeant Pharmaceuticals North America LLC, received notice that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Jublia® (efinaconazole
- AAD Announces Donation of Melanoma Exposed Program from Bristol-Myers Squibbhttps://practicaldermatology.com/news/20140609-aad_announces_donation_of_melanoma_exposed_program_from_bristol-myers_squibb/2459214/Bristol-Myers Squibb donated its Melanoma Exposed™ program to the American Academy of Dermatology (AAD). The donation, provided through a charitable grant, will be used to increase public awareness of skin cancer—including melanoma, the deadliest form of skin cancer—and expand t
- Allergan: Business As Usual Following New Valeant Offerhttps://practicaldermatology.com/news/20140606-allergan_business_as_usual_following_new_valeant_offer/2459215/At Allergan, executives say it is business as usual, even as the board reviews a hefty new offer from Valeant. Valeant last Friday increased its offer to Allergan by $14 per share, “subject to prompt good-faith discussions on a merger agreement.” The new bid values Allergan at about $180 a share and
- Cosmetic Surgery Forum Unveils 2014 Agendahttps://practicaldermatology.com/news/20140606-cosmetic_surgery_forum_unveils_2014_agenda/2459216/The agenda for the 2014 Cosmetic Surgery Forum was recently unveiled. The meeting will take place from December 3 through December 6 at the Palazzo Casino and Resort in Las Vegas, NV. Under course director Joel Schlessinger, MD, this year's meeting will include sessions on cosmetic treatments for me
- Allergan Comments on Pershing Square's and Valeant's Attempt to Remove a Majority of the Members of the Allergan Board of Directorshttps://practicaldermatology.com/news/20140602-allergan_comments_on_pershing_squares_and_valeants_attempt_to_remove_a_majority_of_the_members_of_the_allergan_board_of_directors/2459220/Allergan, Inc. (NYSE: AGN) ("Allergan" or the "Company") today issued the following statement regarding the filing by Pershing Square Capital Management, L.P. ("Pershing Square") of preliminary proxy materials with the Securities and Exchange Commission ("SEC") in order to solicit proxies to call a
- Ichthyosis Patient Raising Awareness, Funds with Hikehttps://practicaldermatology.com/news/20140531-ichthyosis_patient_raising_awareness_funds_with_hike/2459223/To raise awareness of ichthysosis and funds for research, Brian Gass of St. Louis is hiking the Pacific Crest Trail – 2,600 miles from Mexico to Canada, crossing the Sierras, over about 110 days. The 21-year-old college student has the rare genetic skin disease, as do three siblings. The experienced
- Valeant Sells Fillers to Nestle, Ups Allergan Offerhttps://practicaldermatology.com/news/20140530-valeant_sells_fillers_to_nestle_ups_allergan_offer/2459225/Valeant took two significant steps this week in its pursuit of Allergan. In a deal valued at $1.4 billion in cash, Valeant sold the rights to various aesthetic injectables to Nestle. Nestle is expected to operate Restylane, Perlane, Emervel, Sculptra, and Dysport through Galderma. While the dea
- Valeant Pharmaceuticals To Sell Filler And Toxin Assets To Nestle For $1.4 Billionhttps://practicaldermatology.com/news/20140528-valeant_pharmaceuticals_to_sell_filler_and_toxin_assets_to_nestle_for_14_billion/2459228/Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that it has entered into an agreement with Nestle S.A. to sell all rights to Restylane, Perlane, Emervel, Sculptra, and Dysport owned or held by Valeant for $1.4 billion in cash. Nestle expects to complete its acquis
- Allergan Physician Customers Voice Strong Support Following Allergan's Rejection of Unsolicited Proposal to Acquire Companyhttps://practicaldermatology.com/news/20140521-allergan_physician_customers_voice_strong_support_following_allergans_rejection_of_unsolicited_proposal_to_acquire_company/2459232/Allergan, Inc. (NYSE: AGN) ("Allergan" or the "Company") today announced that it has received a strong outpouring of support from its physician customers, their nurses and office staff members, as well as from patient advocacy groups and medical associations, following the Company's rejection of Val
- Michelson Diagnostics Commences New Study with Melanoma Institute of Australiahttps://practicaldermatology.com/news/20140520-michelson_diagnostics_commences_new_study_with_melanoma_institute_of_australia/2459234/The UK based medical device company Michelson Diagnostics has commenced a clinical study to investigate use of Optical Coherence Tomography (OCT) in diagnosing basal cell carcinoma in collaboration with the Melanoma Institute of